Cannabinoids as therapeutic agents in cancer: current status and future implications

Bandana Chakravarti; Janani Ravi; Ramesh K. Ganju

doi:10.18632/oncotarget.2233

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Cannabinoids as therapeutic agents in cancer: current status and future implications

Bandana Chakravarti, Janani Ravi and Ramesh K. Ganju _

PDF | HTML | How to cite

Oncotarget. 2014; 5:5852-5872. https://doi.org/10.18632/oncotarget.2233

Metrics: PDF 9551 views | HTML 39851 views | ?

Abstract

Bandana Chakravarti1,*, Janani Ravi2,* and Ramesh K. Ganju2

1 Molecular Medicine and Biotechnology Department, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

2 Department of Pathology, The Ohio State University, Columbus, Ohio, USA

* These authors contributed equally to this work

Correspondence:

Ramesh K. Ganju, email:

Keywords: Cannabinoid receptors, cannabinoid agonists, cancer, signaling

Received: May 19, 2014 Accepted: July 17, 2014 Published: July 17, 2014

Abstract

The pharmacological importance of cannabinoids has been in study for several years. Cannabinoids comprise of (a) the active compounds of the Cannabis sativa plant, (b) endogenous as well as (c) synthetic cannabinoids. Though cannabinoids are clinically used for anti-palliative effects, recent studies open a promising possibility as anti-cancer agents. They have been shown to possess anti-proliferative and anti-angiogenic effects in vitro as well as in vivo in different cancer models. Cannabinoids regulate key cell signaling pathways that are involved in cell survival, invasion, angiogenesis, metastasis, etc. There is more focus on CB1 and CB2, the two cannabinoid receptors which are activated by most of the cannabinoids. In this review article, we will focus on a broad range of cannabinoids, their receptor dependent and receptor independent functional roles against various cancer types with respect to growth, metastasis, energy metabolism, immune environment, stemness and future perspectives in exploring new possible therapeutic opportunities.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2233

Publication Alerts

Reviews:

Cannabinoids as therapeutic agents in cancer: current status and future implications

Abstract